contents global navigation copyrights

Quick

PRS

Prostate cancer

Account for 10% of total prostate cancer
Rare genetic variants
BRCA1, BRCA2, ETC
common genetic variants
Total number of SNPs
Cancer-related rare genetic changes are very powerful, but account for less than 10% of cancer. Although each effect of common genetic variants is minimal, combined forces can cause cancer
Polygenic Risk Score
Procagen considers the importance of each of the numerous genetic variants and presents the risk of cancer as a score.
Close

AI-based·healthcare

visual image

AI technology is no longer an option, it's a must

Procagen is applying AI technologies into our services in order to efficiently manage and analyze out big data
For this. We are discovering and fostering AI researchers, and promoting product innocation through AI technology in various channels such as consulting with AI experts and collaborating with AI companies.   We are developing an AI SW as a medical device that calculates the current probability of having prostate cancer and this AI SW can be used for prostate biopsy decisio
Close

Intellectual property

9 IPs related to Prostate cancer genetic test and AI Software-as a medical device for prostate biopsy decision-making in PSA grey zone.
(6 registered, 3 applied)
  • patent
  • patent
  • patent
  • patent
  • patent
  • patent

Certification

Close